Marshall Edwards shares crash on PhIII cancer failure

Shares of Marshall Edwards (NASDAQ: MSHL) plummeted yesterday evening after the developer reported that its therapy for ovarian cancer--phenoxodiol--had failed to hit key endpoints in a late-stage trial. Australia's Novogen licensed the drug to Marshall Edwards, which it also holds a majority interest in. Researchers reported that the oral formulation of their drug failed to achieve the kind of progression-free survival or overall survival results they needed to ace the...

Marshall Edwards names experienced biotech CEO to the helm

Marshall Edwards (NASDAQ: MSHLD), a cancer drug developer with operations in Australia and San Diego, has named a new CEO. Daniel Gold, Ph.D., whose biotech resume spans 25 years and includes a stint as CEO of Prospect Therapeutics and a founder's position as chief scientific officer of Favrille, was assigned to the helm of the company. "Dr. Gold has an impressive track record of translating drug discovery into drug development, including all phases of clinical development," said Professor...